newsfilter
← Latest News
Business Wire·

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three